Trial Profile
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 15 Dec 2023 Status changed from active, no longer recruiting to discontinued.
- 07 Jan 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 07 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.